CRISPR Therapeutics Moves Into Off-The-Shelf CAR-T Lead, But Durability Test Awaits

Allogene Remains A Rival Despite Safety Hiatus

 
• By Andrew McConaghie

Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.

CRISPR Therapeutics building
CRISPR Therapeutics is set to begin its pivotal trial in early 2022, but must demonstrate durability in order to challenge established autologous CAR-Ts.

More from Blood and Clotting

More from Therapy Areas